VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2015 | Overview of a Phase II clinical trial of isatuximab

Joseph R Mikhael, MD from the Mayo Clinic, Scottsdale, AZ provides an overview of a Phase II clinical trial of isatuximab (SAR650984) for the treatment of relapsed/refractory multiple myeloma (MM). Isatuximab is an anti-CD38 monoclonal antibody, that is very well tolerated by MM patients, with a response rate of 20-29% based on different cohorts. This drug is now being taken into a larger Phase II trial with over 100 patients taking one single dose of isatuximab.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter